Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma

BACKGROUND: The current standard of treatment for advanced hepatocellular cancer Hepatocellular carcinoma (HCC) is Sorafenib. Data regarding its tolerance and adverse event profile in Indian patients is scarce. MATERIALS AND METHODS: The primary aim of this analysis was to assess the adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostwal, Vikas, Gupta, Tarachand, Chopra, Supriya, Lewis, Sherly, Goel, Mahesh, Patkar, Shraddha, Shetty, Nitin, Ramaswamy, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763620/
https://www.ncbi.nlm.nih.gov/pubmed/29404288
http://dx.doi.org/10.4103/sajc.sajc_44_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763620/
https://www.ncbi.nlm.nih.gov/pubmed/29404288
http://dx.doi.org/10.4103/sajc.sajc_44_17

Ejemplares similares